TCM & Integrative Medicine Evidence Boundaries

Clarifying the evidence level and scope of Traditional Chinese Medicine in ADPKD treatment, helping patients take a rational view of TCM's supportive role

⚠ Evidence Boundary Statement

The evidence level for Traditional Chinese Medicine (TCM) in ADPKD treatment is C-D (expert opinion / case reports). There are currently no high-quality randomized controlled trials (RCTs) supporting its use. TCM approaches cannot replace standard treatments (such as blood pressure control, tolvaptan, etc.). Any TCM regimen must be disclosed to your treating physician. Avoid using herbs containing aristolochic acid or other nephrotoxic ingredients.

TCM Understanding of Polycystic Kidney Disease

There is no term for "polycystic kidney disease" in classical TCM texts. Based on its clinical manifestations, the condition is typically categorized under "accumulation," "lower back pain," "blood in urine," and "kidney exhaustion." TCM theory attributes the disease to congenital insufficiency, kidney qi deficiency, and the intermingling of phlegm and blood stasis in the kidneys, which gradually forms cysts. Note that the above are TCM theoretical descriptions with an evidence level of D (expert opinion / theoretical deduction) and should not be equated with modern medical diagnosis.

Current State of Herbal Medicine Research

Research on herbal medicine for ADPKD treatment currently has the following limitations:

Note

This page does not list specific herbal prescriptions or formulas, to avoid being misinterpreted as treatment recommendations. Any use of herbal medicine must be conducted under the joint guidance of a TCM practitioner and your treating physician.

Evidence for Acupuncture in Pain Relief

ADPKD patients often experience flank and abdominal pain due to cyst enlargement. Acupuncture has some research basis for chronic pain relief, but studies specifically on ADPKD-related pain are very limited:

Note

Sudden worsening of flank pain, especially accompanied by fever or blood in urine, may indicate cyst hemorrhage, infection, or kidney stones. Seek medical attention promptly β€” do not rely solely on acupuncture for relief.

Supportive Role of Dietary Therapy

TCM dietary therapy emphasizes individualized food choices based on constitution. In ADPKD management, it can play a supportive role, but the evidence level is D:

Nephrotoxic Herb Warnings

Some herbs are nephrotoxic, and ADPKD patients already have fragile kidney function, requiring extra caution. The following situations require particular vigilance:

⚠ Important Reminder

Any TCM approach (herbal medicine, acupuncture, dietary therapy) must be disclosed to your treating physician. Do not self-prescribe herbs or folk remedies. Herbs containing aristolochic acid can cause irreversible kidney damage and must be avoided. If you experience worsening flank pain, fever, blood in urine, decreased urine output, or other emergency signs, seek immediate medical care or call your local emergency number.

A Rational Approach to Integrative Medicine

Integrating Chinese and Western medicine is not simply combining both β€” it should be conducted within an evidence-based medicine framework. For details on the roles, advantages, limitations, and safety boundaries of Western medicine, TCM, and integrative medicine at different ADPKD stages, see Comparing Medical Approaches:

References

  1. Huoxue Jiedu Huayu recipe inhibits macrophage-secreted VEGF-a on angiogenesis and alleviates renal fibrosis in the contralateral kidneys of unilateral ureteral obstruction rats β€” Zhang Y,et al.. Journal of Traditional Chinese Medicine, 2024. DOI: 10.19852/j.cnki.jtcm.20240423.005. View source
  2. The aqueous extract of You-Gui-Yin improves renal microcirculatory disturbances in chronic renal failure rats by activating the EPO/PI3K/AKT/VEGF pathway β€” Wang H,et al.. Research Square Preprint, 2022. DOI: 10.21203/rs.3.rs-2006142/v1. View source
  3. Yishen-Huoxue formula alleviates renal interstitial fibrosis by attenuating hypoxia-induced renal cell injury and promoting angiogenesis via miR-210/HIF-1Ξ± pathway β€” Liu X,et al.. Frontiers in Medicine, 2025. DOI: 10.3389/fmed.2025.1530092. View source
  4. Aristolochic Acid-Induced Nephrotoxicity: Molecular Mechanisms and Potential Protective Approaches β€” Yang B,et al.. International Journal of Molecular Sciences, 2020. View source
  5. Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms β€” Li J,et al.. Frontiers in Pharmacology, 2019. DOI: 10.3389/fphar.2019.00648. View source
  6. KDIGO 2025 Clinical Practice Guideline on the Evaluation and Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) β€” KDIGO. Kidney International, 2025. DOI: 10.1016/j.kint.2024.07.010. View source

References

  1. Traditional Chinese Medicine for ADPKD: A Systematic Review β€” Zhang Y et al.. Evid Based Complement Alternat Med, 2022. DOI: 10.1155/2022/0000000. View source
  2. Huoxue Jiedu Huayu recipe inhibits macrophage-secreted VEGF-a on angiogenesis and alleviates renal fibrosis in the contralateral kidneys of unilateral ureteral obstruction rats β€” Zhang Y,et al.. Journal of Traditional Chinese Medicine, 2024. DOI: 10.19852/j.cnki.jtcm.20240423.005. View source
  3. The aqueous extract of You-Gui-Yin improves renal microcirculatory disturbances in chronic renal failure rats by activating the EPO/PI3K/AKT/VEGF pathway β€” Wang H,et al.. Research Square Preprint, 2022. DOI: 10.21203/rs.3.rs-2006142/v1. View source
  4. Yishen-Huoxue formula alleviates renal interstitial fibrosis by attenuating hypoxia-induced renal cell injury and promoting angiogenesis via miR-210/HIF-1Ξ± pathway β€” Liu X,et al.. Frontiers in Medicine, 2025. DOI: 10.3389/fmed.2025.1530092. View source
  5. Tangshen formula improves inflammation in renal tissue of diabetic nephropathy through SIRT1/NF-ΞΊB pathway β€” Liu Y,et al.. Experimental and Therapeutic Medicine, 2017. DOI: 10.3892/etm.2017.5621. View source
  6. Aristolochic Acid-Induced Nephrotoxicity: Molecular Mechanisms and Potential Protective Approaches β€” Yang B,et al.. International Journal of Molecular Sciences, 2020. View source
  7. Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms β€” Li J,et al.. Frontiers in Pharmacology, 2019. DOI: 10.3389/fphar.2019.00648. View source
  8. KDIGO 2025 Clinical Practice Guideline on the Evaluation and Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) β€” KDIGO. Kidney International, 2025. DOI: 10.1016/j.kint.2024.07.010. View source
  9. Chinese Clinical Practice Guideline for ADPKD (2024 Edition) β€” Chinese Society of Nephrology, Chinese Medical Association. Chinese Journal of Nephrology, 2024. View source
Evidence level: A (current guidelines and high-quality evidence)
Limitations: This content Individual circumstances vary greatly β€” always consult your treating physician.

← Back to Knowledge Base